Codexis, Inc. (NASDAQ:CDXS)
| Market Cap | 138.75M-48.8% |
| Revenue (ttm) | 77.68M+35.9% |
| Net Income | -30.72M+52.7% |
| EPS | -0.34+59.5% |
| Shares Out | 107.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 929,594 |
| Open | 1.30 |
| Previous Close | 1.32 |
| Day's Range | 1.27 - 1.34 |
| 52-Week Range | 0.96 - 2.98 |
| Beta | 2.55 |
| Analysts | Buy |
| Price Target | 8.00(+520.16%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CDXS
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CDXS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CDXS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CDXS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CDXS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CDXS Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CDXS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CDXS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CDXS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $5.23M |
| IWMiShares Russell 2000 ETF | $3.36M |
| VXFVanguard Extended Market ETF | $1.54M |
| IWOiShares Russell 2000 Growth ETF | $1.05M |
| IBBiShares Biotechnology ETF | $1.03M |
| VTWOVanguard Russell 2000 ETF | $846.59K |
Estimated from each fund’s disclosed top holdings × AUM
CDXS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CDXS’s recent data — informational, not investment advice